Clinical performance of a new multiplex assay for the detection of HIV-1, HIV-2, HCV, HBV, and HEV in blood donations in Catalonia (Spain).
Journal
Transfusion
ISSN: 1537-2995
Titre abrégé: Transfusion
Pays: United States
ID NLM: 0417360
Informations de publication
Date de publication:
Nov 2023
Nov 2023
Historique:
revised:
12
08
2023
received:
12
07
2023
accepted:
12
08
2023
medline:
16
11
2023
pubmed:
28
9
2023
entrez:
28
9
2023
Statut:
ppublish
Résumé
Commercial multiplex nucleic acid tests (NATs) for HIV-1/HIV-2/HCV/HBV are widely used in developed countries to screen blood donations. HEV NAT screening has been implemented in some blood banks but is tested with a different assay. This study describes the clinical sensitivity and specificity of the Procleix® UltrioPlex E (UPxE) assay on the automated Procleix Panther® system for the simultaneous detection of HIV-1/HIV-2/HCV/HBV/HEV. To evaluate routine performance, 10,138 donations were tested in parallel with UPxE (in ID-NAT) and current assays (Procleix Ultrio Elite [UE] assay in ID-NAT and Procleix HEV assay in pool of 16). To assess clinical sensitivity, archived donations positive for HCV, HIV-1, HBV, HEV, or occult HBV infection (OBI) were tested (n = 104-186). Five donations were initially reactive (IR) with UPxE; none of them were reactive with current assays. Two of the three samples IR for HIV-1/HIV-2/HCV/HBV were confirmed positive for HBV (HBV NAT and/or anti-HBV core positive) and classified as OBI. The two samples IR for HEV were confirmed positive (Procleix HEV assay in ID-NAT and in-house RT-PCR HEV assay). One sample IR for HIV-1/HIV-2/HCV/HBV with UPxE and another with UE were not confirmed. UPxE showed a specificity of 99.99% for HIV-1/HIV-2/HCV/HBV and 100% for HEV. Comparable sensitivities were observed for HIV-1, HCV, HBV, OBI, and HEV samples tested in the UPxE, UE, and Procleix HEV assays. UPxE may provide an efficient solution for the simultaneous detection of HIV-1, HIV-2, HCV, HBV, and HEV in blood donations in a single test.
Sections du résumé
BACKGROUND
BACKGROUND
Commercial multiplex nucleic acid tests (NATs) for HIV-1/HIV-2/HCV/HBV are widely used in developed countries to screen blood donations. HEV NAT screening has been implemented in some blood banks but is tested with a different assay.
STUDY DESIGN AND METHODS
METHODS
This study describes the clinical sensitivity and specificity of the Procleix® UltrioPlex E (UPxE) assay on the automated Procleix Panther® system for the simultaneous detection of HIV-1/HIV-2/HCV/HBV/HEV. To evaluate routine performance, 10,138 donations were tested in parallel with UPxE (in ID-NAT) and current assays (Procleix Ultrio Elite [UE] assay in ID-NAT and Procleix HEV assay in pool of 16). To assess clinical sensitivity, archived donations positive for HCV, HIV-1, HBV, HEV, or occult HBV infection (OBI) were tested (n = 104-186).
RESULTS
RESULTS
Five donations were initially reactive (IR) with UPxE; none of them were reactive with current assays. Two of the three samples IR for HIV-1/HIV-2/HCV/HBV were confirmed positive for HBV (HBV NAT and/or anti-HBV core positive) and classified as OBI. The two samples IR for HEV were confirmed positive (Procleix HEV assay in ID-NAT and in-house RT-PCR HEV assay). One sample IR for HIV-1/HIV-2/HCV/HBV with UPxE and another with UE were not confirmed. UPxE showed a specificity of 99.99% for HIV-1/HIV-2/HCV/HBV and 100% for HEV. Comparable sensitivities were observed for HIV-1, HCV, HBV, OBI, and HEV samples tested in the UPxE, UE, and Procleix HEV assays.
DISCUSSION
CONCLUSIONS
UPxE may provide an efficient solution for the simultaneous detection of HIV-1, HIV-2, HCV, HBV, and HEV in blood donations in a single test.
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
2098-2105Subventions
Organisme : Grifols
Informations de copyright
© 2023 AABB.
Références
Roth WK. History and future of nucleic acid amplification technology blood donor testing. Transfus Med Hemotherapy. 2019;46:67-75.
Roth WK, Busch MP, Schuller A, Ismay S, Cheng A, Seed CR, et al. International survey on NAT testing of blood donations: expanding implementation and yield from 1999 to 2009. Vox Sang. 2012;102:82-90.
Busch MP, Bloch EM, Kleinman S. Prevention of transfusion-transmitted infections. Blood. 2019;133:1854-1864.
Hewitt PE, Ijaz S, Brailsford SR, Brett R, Dicks S, Haywood B, et al. Hepatitis E virus in blood components: a prevalence and transmission study in Southeast England. Lancet. 2014;384:1766-1773.
Riveiro-Barciela M, Bes M, Quer J, Valcarcel D, Piriz S, Gregori J, et al. Thrombotic thrombocytopenic purpura relapse induced by acute hepatitis E transmitted by cryosupernatant plasma and successfully controlled with ribavirin. Transfusion. 2018;58:2501-2505.
Riveiro-Barciela M, Sauleda S, Quer J, Salvador F, Gregori J, Pirón M, et al. Red blood cell transfusion-transmitted acute hepatitis E in an immunocompetent subject in Europe: a case report. Transfusion. 2016;57:244-247.
Gallian P, Pouchol E, Djoudi R, Lhomme S, Mouna L, Gross S, et al. Transfusion-transmitted hepatitis E virus infection in France. Transfus Med Rev. 2019;33:146-153.
Tanaka A, Hoshi Y, Hasegawa T, Sakata H, Furui Y, Goto N, et al. The current status of transfusion-transmitted hepatitis e virus infection in Japan. Jpn J Transfus Cell Ther. 2020;66:531-537.
Boland F, Martinez A, Pomeroy L, O'Flaherty N. Blood donor screening for hepatitis E virus in the European Union. Transfus Med Hemotherapy. 2019;46:95-103.
Cordes AK, Goudeva L, Lütgehetmann M, Wenzel JJ, Behrendt P, Wedemeyer H, et al. Risk of transfusion-transmitted hepatitis E virus infection from pool-tested platelets and plasma. J Hepatol. 2022;76:46-52.
Denner J, Pischke S, Steinmann E, Blümel J, Glebe D. Why all blood donations should be tested for hepatitis E virus (HEV). BMC Infect Dis. 2019;19:541.
Laperche S, Maugard C, Lhomme S, LeCam S, Ricard C, Dupot I, et al. Seven years (2015-2021) of blood donor screening for HEV-RNA in France: lessons and perspectives. Blood Transfus. 2023;21:110-118.
Sakata H, Matsubayashi K, Iida J, Nakauchi K, Kishimoto S, Sato S, et al. Trends in hepatitis E virus infection: analyses of the long-term screening of blood donors in Hokkaido, Japan, 2005-2019. Transfusion. 2021;61:3390-3401.
Bes M, Costafreda MI, Riveiro-Barciela M, Piron M, Rico A, Quer J, et al. Effect of hepatitis E virus RNA universal blood donor screening, Catalonia, Spain, 2017-2020. Emerg Infect Dis. 2022;28:157-165.
Harvala H, Reynolds C, Brailsford S, Davison K. Fulminant transfusion-associated hepatitis E virus infection despite screening, England, 2016-2020. Emerg Infect Dis. 2022;28:1805-1813.
Tedder RS, Ijaz S, Kitchen A, Ushiro-Lumb I, Tettmar KI, Hewitt P, et al. Hepatitis E risks: pigs or blood-that is the question. Transfusion. 2017;57:267-272.
Bes M, Vargas V, Piron M, Casamitjana N, Esteban JI, Vilanova N, et al. T cell responses and viral variability in blood donation candidates with occult hepatitis B infection. J Hepatol. 2012;56:765-774.
Said ZNA. An overview of occult hepatitis B virus infection. World J Gastroenterol. 2011;17:1927-1938.
Esposito A, Sabia C, Iannone C, Nicoletti GF, Sommese L, Napoli C. Occult hepatitis infection in transfusion medicine: screening policy and assessment of current use of anti-HBc testing. Transfus Med Hemotherapy. 2017;44:263-272.
Seed CR, Allain JP, Lozano M, Laperche S, Gallian P, Gross S, et al. International forum on occult hepatitis B infection and transfusion safety. Vox Sang. 2019;114:397-406.